Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2''-O-[N-(3-(aminopropyl)2-aminoethyl]paromomycin is a synthetic derivative of paromomycin, an aminoglycoside antibiotic. This compound is part of research efforts to develop next-generation aminoglycosides with improved antibacterial activity and reduced toxicity, particularly ototoxicity and nephrotoxicity. Like its parent compound, it acts by binding to specific sites on bacterial rRNA, disrupting protein synthesis and leading to bactericidal effects. The modification at the 2'' position aims to enhance selectivity for bacterial ribosomes over mammalian ones and potentially evade common resistance mechanisms[1][2]. Its primary development context is as an experimental antibacterial agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2''-O-[N-(3-(aminopropyl)2-aminoethyl]paromomycin.